Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firmonertinib - Allist Pharmaceuticals/ArriVent Biopharma

Next Previous
Drug Profile

Firmonertinib - Allist Pharmaceuticals/ArriVent Biopharma

Alternative Names: Alflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; AST-2818; Furmonertinib; Furmonertinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Iflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Ivesa; Vometinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allist Pharmaceuticals
  • Developer Allist Pharmaceuticals; ArriVent Biopharma
  • Class Amides; Antineoplastics; Diamines; Fluorinated hydrocarbons; Indoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO, Tablet)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO, Tablet)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top